FDA Drug Topics: Cannabis and Cannabis-Derived Products – For Healthcare Practitioners - March 28, 2023

FDA Drug Topics: Cannabis and Cannabis-Derived Products – For Healthcare Practitioners – March 28, 2023 FDA Drug Topics: Cannabis and Cannabis-Derived Products – For Healthcare Practitioners – March 28, 2023 Anonymous (not verified) Wed, 02/22/2023 – 11:23

Detailed Description

On Tuesday, March 28, 2023, CDER’s Office of Communication, Division of Drug Information (DDI) will host a webinar titled: FDA Drug Topics: Cannabis and Cannabis-Derived Products – For Healthcare Practitioners. This webinar will provide a general understanding of the Cannabis sativa L. plant and how

Center

Center for Drug Evaluation and Research

FDA’s Division of Drug Information in the Center for Drug Evaluation and Research (CDER) is excited to present a series of educational webinars targeting the needs of all health care professionals and students, including physicians, physician assistants, nurses, pharmacists, and pharmacy technicians. Interact with FDA staff from a variety of divisions and learn more about the FDA and drug regulation!

On Tuesday, March 28, 2023, CDER’s Office of Communication, Division of Drug Information (DDI) will host a webinar titled: FDA Drug Topics: Cannabis and Cannabis-Derived Products – For Healthcare Practitioners. This webinar will provide a general understanding of the Cannabis sativa L. plant and how products are generally produced utilizing cannabis raw materials. The presentation will explain why manufacturing controls surrounding cannabis and cannabis-derived products are an integral part of protecting the public health. Will provide attendees with greater knowledge of the many products available on the marketplace, a discussion on potential benefits and risks, ways to report adverse events associated with these products to FDA, as well as suggestions on how to create a safe space to discuss patient use of these products.

Activity Outline and Continuing Education Information

If you have never attended an Adobe Connect meeting before:

Test your connection: Adobe Connect Diagnostic Test
Get a quick overview: Discover Adobe Connect Solutions

Adobe, the Adobe logo, Acrobat and Adobe Connect are either registered trademarks or trademarks of Adobe Systems Incorporated in the United States and/or other countries.

Resources For You

Short Title

FDA Drug Topics: Cannabis and Cannabis-Derived Products – For Healthca

Source Organization

FDA

Content Owner

Office of Communications

Publish Date

Wed, 02/22/2023 – 11:24

Review Date

Thu, 02/22/2024 – 00:00

Last Reviewed Date

Wed, 02/22/2023 – 00:00

Site Structure

FDA Pharmacy Student Experiential Program

Navigational Page

Off

Bulk Approved

Off

Display Short Description

Off

First Publish Date

Wed, 02/22/2023 – 11:24

Generic Boolean

Off

Language

English

Number of Related Information to Display

Add Subscription Box

Off

Display Short Title

Off

#CBD #Hemp http://www.fda.gov/about-fda/fda-pharmacy-student-experiential-program/fda-drug-topics-cannabis-and-cannabis-derived-products-healthcare-practitioners-march-28-2023 February 22, 2023 4:23 pm

Blah Blah Blah

Copyright 1994-2024 Richard Rose, all rights reserved. Any views expressed herein are the personal opinion of Richard Rose. This is a noncommercial public service. There are no warranties whatsoever as to the legality, suitability, ownership, purpose, or accuracy of this information. I am not a doctor or a lawyer. If you have medical questions, please seek a medical professional. If you have legal questions, please seek a legal professional. Information found here is not intended to diagnose, cure, treat, or prevent any disease. These statements and subsequent links found here have not been evaluated by the U.S. Food and Drug Administration (FDA). Hemp is not subject to international drug controls and is grown legally around the world. The information posted here is for educational purposes only and is not to be considered legal or medical advice, and is not intended to replace consultation with a qualified legal or medical professional. This website uses cookies. By continuing to use this service, you agree to their use. This is provided on an “as is,” “as available” basis without warranties of any kind, express or implied. The user assumes all responsibility and risk for the use of this website. Links are provided only as an informational resource, and it should not be implied that we own, recommend, endorse or approve of any of the content at the linked sites, nor are we responsible for their content. Unless otherwise stated, nobody pays us nuttin’ to post content, and we have no sponsors unlike NASCAR. By providing your email address to us you agree to be on the free The Richard Rose Report… This Week mailing list; you may unsubscribe at any time. There is no charge. To learn more about how we collect, keep, and process your private information in compliance with GDPR, please view our privacy policy via a link at the bottom of this page. Void where prohibited. Specifications subject to change without notice. If you don’t agree with the above please leave immediately. All patents, service marks, trademarks, and copyrights are the property of their respective owners. To the best of my knowledge, all Articles, Downloads, and Posts authored by RR are absolutely not written with any type of AI, just a human brain. Grammarly and autocorrect might be used to make minor edits. Posts authored under CannaSearch Daily are written by the original external poster, and no claim is made for those. It’s obvious that GPT language models will be deployed everywhere, but their accuracy is still low so I avoid them for now. Plus writers write.